These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 14537107)

  • 1. Positron emission tomography and drug discovery: contributions to the understanding of pharmacokinetics, mechanism of action and disease state characterization.
    Klimas MT
    Mol Imaging Biol; 2002 Oct; 4(5):311-37. PubMed ID: 14537107
    [TBL] [Abstract][Full Text] [Related]  

  • 2. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ligand-receptor interactions as studied by PET: implications for drug development.
    Hietala J
    Ann Med; 1999 Dec; 31(6):438-43. PubMed ID: 10680859
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of positron emission tomography in the discovery and development of new drugs; as studied in laboratory animals.
    Roselt P; Meikle S; Kassiou M
    Eur J Drug Metab Pharmacokinet; 2004; 29(1):1-6. PubMed ID: 15151164
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Application of cardiac molecular imaging using positron emission tomography in evaluation of drug and therapeutics for cardiovascular disorders.
    Yoshinaga K; Chow BJ; dekemp RA; Thorn S; Ruddy TD; Davies RA; DaSilva JN; Beanlands R
    Curr Pharm Des; 2005; 11(7):903-32. PubMed ID: 15777243
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent applications of positron emission tomographic (PET) imaging in psychiatric drug discovery.
    Zimmer L
    Expert Opin Drug Discov; 2024 Feb; 19(2):161-172. PubMed ID: 37948046
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Small Molecule PET Tracers in Drug Discovery.
    Donnelly DJ
    Semin Nucl Med; 2017 Sep; 47(5):454-460. PubMed ID: 28826520
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Operational radiation safety for PET-CT, SPECT-CT, and cyclotron facilities.
    Zanzonico P; Dauer L; St Germain J
    Health Phys; 2008 Nov; 95(5):554-70. PubMed ID: 18849690
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Application of in vivo animal models to characterize the pharmacokinetic and pharmacodynamic properties of drug candidates in discovery settings.
    Amore BM; Gibbs JP; Emery MG
    Comb Chem High Throughput Screen; 2010 Feb; 13(2):207-18. PubMed ID: 20053166
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Label-free assay for the assessment of nonspecific binding of positron emission tomography tracer candidates.
    Assmus F; Seelig A; Gobbi L; Borroni E; Glaentzlin P; Fischer H
    Eur J Pharm Sci; 2015 Nov; 79():27-35. PubMed ID: 26341407
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-invasive imaging in experimental medicine for drug development.
    Matthews PM; Rabiner I; Gunn R
    Curr Opin Pharmacol; 2011 Oct; 11(5):501-7. PubMed ID: 21570913
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Receptor Occupancy Imaging Studies in Oncology Drug Development.
    Burvenich IJG; Parakh S; Parslow AC; Lee ST; Gan HK; Scott AM
    AAPS J; 2018 Mar; 20(2):43. PubMed ID: 29520671
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Can positron emission tomography facilitate paediatric drug development?
    Zimmer L
    Fundam Clin Pharmacol; 2008 Dec; 22(6):595-8. PubMed ID: 19049660
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The use of 18F-Fluoro-deoxy-glucose positron emission tomography (18F-FDG PET) as a non-invasive pharmacodynamic biomarker to determine the minimally pharmacologically active dose of AZD8835, a novel PI3Kα inhibitor.
    Maynard J; Emmas SA; Ble FX; Barjat H; Lawrie E; Hancox U; Polanska UM; Pritchard A; Hudson K
    PLoS One; 2017; 12(8):e0183048. PubMed ID: 28806782
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PET and SPECT imaging of the opioid system: receptors, radioligands and avenues for drug discovery and development.
    Lever JR
    Curr Pharm Des; 2007; 13(1):33-49. PubMed ID: 17266587
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Applications of positron emission tomography in the development of molecular targeted cancer therapeutics.
    Solomon B; McArthur G; Cullinane C; Zalcberg J; Hicks R
    BioDrugs; 2003; 17(5):339-54. PubMed ID: 14498764
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The application of positron emission tomography (PET) imaging in CNS drug development.
    Suridjan I; Comley RA; Rabiner EA
    Brain Imaging Behav; 2019 Apr; 13(2):354-365. PubMed ID: 30259405
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PET Molecular Imaging in Drug Development: The Imaging and Chemistry Perspective.
    Nerella SG; Singh P; Sanam T; Digwal CS
    Front Med (Lausanne); 2022; 9():812270. PubMed ID: 35295604
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-invasive methods to study drug disposition: positron emission tomography. Detection and quantification of brain receptors in man.
    Sadzot B; Franck G
    Eur J Drug Metab Pharmacokinet; 1990; 15(2):135-42. PubMed ID: 2166673
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Small-animal PET: a promising, non-invasive tool in pre-clinical research.
    Schnöckel U; Hermann S; Stegger L; Law M; Kuhlmann M; Schober O; Schäfers K; Schäfers M
    Eur J Pharm Biopharm; 2010 Jan; 74(1):50-4. PubMed ID: 19482080
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.